Senior Manager / Manager, Proposal Writer, Business Development Operations - Level DOE
Job Purpose / Summary
Responsible for tactical support and follow-up within Business Development Operations Department, in accordance with any applicable CTI Standard Operating Procedures (SOPs). This position focuses on new client targeting, material development, and support activities for the Business Development (BD) Operations group.
What You'll Do
Develop RFI/RFP responses
Maintain internal library of therapeutic experience summaries
Coordinate responses to request for information (RFI)
Strategically position in-house data and external research to support business development efforts
Assist in the development of capabilities / bid defense presentations
Develop sales tools (ie, new therapeutic and/or service summaries)
Liaise with feasibility department to support new business opportunities
Assist with marketing initiatives as needed
What You'll Bring
2 to 6 years in pharmaceutical, clinical, or related experience
Bachelor’s degree
Why CTI?
We support career progression – We have a structured mentoring program to provide the support you need to move forward
We value education and training – We provide tuition reimbursement, partner with universities and colleges to create programs in our field, and have a dedicated training department
We value our people - We have never had a layoff in our 20-year history, support a work-life balance, and have provided cash bonuses every year for the past decade
Our culture is unparalleled – We've received multiple awards recognizing CTI as one of the best places to work in the greater Cincinnati area, as well as one of the top CROs in the industry
We are looking toward the future – We have had a consistent double-digit growth rate over the last decade, invest in cutting-edge technology, and pride ourselves on our average 95% annual retention rate (a recent report found that the average turnover for CROs in the US was 30%)
Our work makes a difference – We focus our work on treatments for chronically and critically-ill patients, who are depending on us to bring these life-changing therapies to market